医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Advantech Withdraws Participation to Embedded World 2020 Due to CoronaVirus Health and Safety Concerns

2020年02月24日 PM10:56
このエントリーをはてなブックマークに追加


 

MUNICH

In response to the current outbreak of novel coronavirus (COVID-19), Advantech (stock code: 2395), global leader in IoT, wants to inform its customers, partners and employees that we have regretfully decided to withdraw our participation to Embedded World (February 25th -27th) and all activities scheduled for this event.. For Advantech, the health of our employees, customers and partners is of the utmost importance. We would like to thank the Nürnberg Messe GmbH for its support and understanding.

– Ends –

About Embedded-IoT Group

As leader in the embedded market, the Advantech Embedded-IoT group not only delivers a wide range of embedded design-in services but also develops a series of integrated IoT solutions and services to minimize uncertainty and risk for customers approaching the IoT market. Advantech Integrated IoT Solutions include everything from sensor nodes, to gateways, to WISE-PaaS IoT software and much more. (Embedded-IoT.advantech.com)

About Advantech

Advantech’s corporate vision is to enable an intelligent planet. The company is a global leader in the fields of IoT intelligent systems and embedded platforms. To embrace the trends of IoT, big data, and artificial intelligence, Advantech promotes IoT hardware and software solutions with the Edge Intelligence WISE-PaaS core to assist business partners and clients in connecting their industrial chains. Advantech is also working with business partners to co-create business ecosystems that accelerate the goal of industrial intelligence. (www.advantech.com)

View source version on businesswire.com: https://www.businesswire.com/news/home/20200224005567/en/

CONTACT

Press Contact eIoT:

Advantech Europe B.V.

Daniel Piper

Tel: +49 173 659 9848

daniel.piper@advantech.de

Press Contact Corporate Europe

Advantech Europe B.V.

Karla Ferrer

Tel: +33 (0) 141 19 79 22

Karla.ferrer@advantech.fr

Press Contact Corporate Headquarters

Jennifer Huang

Tel: +886 2 2792-7818 ext.7388

Jennifer.huang@advantech.tw

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続